Strategic License Agreements - Additional Information (Details) $ in Thousands	1 Months Ended		3 Months Ended
	Jul. 31, 2021 USD ($)	Jun. 30, 2021 USD ($)	Mar. 31, 2022 USD ($)	Mar. 31, 2021 USD ($) $ / shares € / shares	Dec. 31, 2021 USD ($)
Research And Development Arrangement Contract To Perform For Others [Line Items]
Revenue recognized			$ 1,362	$ 0
Current deferred revenue			2,069		$ 2,359
Contract liabilities			2,809	0	$ 3,576
Contract assets			0	0
Immedica Pharma AB
Research And Development Arrangement Contract To Perform For Others [Line Items]
Non refundable payment received				$ 21,500
Percentage of payment for cost incurred in PIP trial				50.00%
Additional upfront payment to be received				$ 125,000
Rate of revenue share				25.00%
Reimbursement	$ 3,000
Upfront payment				$ 21,500
Modified transaction price	25,100
Estimated amount incurred	$ 3,600
Allocation price net				12,000
Total deferred revenue			2,800	21,500
Current deferred revenue			$ 2,100	$ 19,200
Immedica Pharma AB | Maximum
Research And Development Arrangement Contract To Perform For Others [Line Items]
Percentage of payment for cost incurred in PIP trial				50.00%
Costs incurred in performing PIP the trial				$ 1,800
Milestone payments exchange rate | € / shares				1.00
Immedica Pharma AB | Minimum
Research And Development Arrangement Contract To Perform For Others [Line Items]
Milestone payments exchange rate | $ / shares				1.13
License Agreements | Immedica Pharma AB
Research And Development Arrangement Contract To Perform For Others [Line Items]
Research agreement date			2021-03
Revenue recognized		$ 12,000
PEACE Trial and BLA Package | Immedica Pharma AB
Research And Development Arrangement Contract To Perform For Others [Line Items]
Allocated amount of transaction price			$ 9,600
Revenue recognized			1,400	$ 0
PIP Trial | Immedica Pharma AB
Research And Development Arrangement Contract To Perform For Others [Line Items]
Allocated amount of transaction price			$ 3,500